Seqirus announced US$140 million manufacturing expansion of its Holly Springs manufacturing facility in North Carolina.
The expansion of the manufacturing facility will allow Seqirus to enhance capacity for formulation, fill and finish manufacturing of cell-based and adjuvanted influenza vaccines for global markets.
In addition to the current workforce of 600 employees, nearly 120 permanent highly skilled jobs will be created.
The new facility construction is expected to be complete by 2020.
It supports increased fill and finish of influenza vaccine doses as well as enabling Seqirus to produce pandemic influenza vaccines more rapidly.
The manufacturing facility will provide innovative solutions, including cell-based vaccines, to help reduce deaths and severe illness caused by influenza.
The Holly Springs manufacturing facility was purpose-built in partnership with the Biomedical Advanced Research and Development Authority (BARDA) to combat pandemic influenza threats.
The new facility will use cell-based technology as a highly scalable method of production and has the potential to transform the global influenza vaccine market.
|Schedule||Scheduled to be completed by 2020|